In plain terms

The claim being assessed: Accumulated senescent cells causally drive age-related organismal dysfunction, and selective removal of these cells extends mammalian lifespan or human healthspan.

Where the evidence stands: Β — Association only. The pattern is real and repeatable, but nobody has shown it causes anything.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: Preregistered weakest-link aggregation yields Β (SC1 Β, SC2 Ε, SC3 Ε). The causal-contribution sensitivity is Ε, not mere association. The application score acknowledges mouse survival and functional trajectories; human healthspan alone remains Γ. The bundled letter must not erase the causal contribution evidence or turn a real cellular state into a refuted phenomenon.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means for Senescence: Driver vs Byproduct

Claim being assessed: Accumulated senescent cells causally drive age-related organismal dysfunction, and selective removal of these cells extends mammalian lifespan or human healthspan.. This review asks whether the proposed factor causes the health outcome—not just whether the two appear together. For the wording assessed here, the evidence is rated Association only (HSEF Β; Moderate confidence). The pattern is real and repeatable, but nobody has shown it causes anything. That rating applies to this claim and scope; it does not mean the biological process is irrelevant in every setting.

Implications for health and treatment: This is an assessment of a causal explanation, not proof that a particular supplement, diet, test, or treatment improves health. A treatment claim needs studies that test the intervention in people and measure meaningful benefits and harms. These findings can help frame research and informed clinical questions, but they do not identify what is right for one person.

Limits for individual care: Evidence from cells, animals, associations, or a plausible mechanism may not predict what happens in people. The grade is limited to the exact claim, outcomes, and sources reviewed, and it is not a diagnosis or an individual forecast. Do not start, stop, or change care based on this page; discuss personal decisions with a qualified clinician.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

This assessment rests on 62 sources and 66 individually checked claims. 66 of those claims were verified against the original paper.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

ID	Sub-claim	Type	Level	Pivotal card
SC1	Senescent cells accumulate with normal age.	existence	Β	—
SC2	Senescent cells are causally required for defined age-related dysfunction.	necessity	Ε	Card ↗
SC3	Senolytic intervention extends mammalian lifespan or human healthspan.	application	Ε	Card ↗

Visual Evidence Cards · Pivotal Subclaims

Pivotal subclaim illustrations

Dark-theme simulated-micrograph renders and concise causal evidence summaries for the pivotal subclaims that govern this review's grade. Click any card to inspect the master 2400×2400 render.

Master 2400×2400 render ↗

Master 2400×2400 render ↗

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 62 primary reports; claims: 66; verified: 66; unverified: 0. Verification is bounded attribution. Access: 5 partial-body and 57 complete abstract/status examinations. Cutoff: 2026-10-05. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 0 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Senescent and marker-high cell populations causally contribute to defined mouse dysfunctions; durable human healthspan benefit remains unproved.

Deciding experiment: Register independent-site adult clearance of a multimarker-defined cell lineage with orthogonal non-marker-dependent targeting, then restore the targeted cells or a specified SASP mediator; pair this with a powered randomized clinical trial using a prospectively defined tissue-burden stratum.

Belief versus evidence: Preregistered weakest-link aggregation yields Β (SC1 Β, SC2 Ε, SC3 Ε). The causal-contribution sensitivity is Ε, not mere association. The application score acknowledges mouse survival and functional trajectories; human healthspan alone remains Γ. The bundled letter must not erase the causal contribution evidence or turn a real cellular state into a refuted phenomenon.

Best-supported rival: Context-dependent disease amplifier. Cell-type-resolved adult clearance with restoration of the targeted cell or its defined secretome would distinguish SASP-mediated amplification from structural loss and broad immune remodeling.

COMPETING MECHANISTIC MODELS

Rank 1: Context-dependent disease amplifier (Ε). Specific persistent populations amplify tissue dysfunction while other states support repair. Clearance/transfer contrasts and cell-type-specific harms converge on a mapped contextual effect. This does not explain every upstream initiating lesion or the demographic rate of aging.

Rank 2: SASP-mediated dysfunction (Ε). Secreted factors propagate harmful or reparative effects depending on duration and context. Paracrine skin models, tissue transfer and SASP-linked phenotypes support local pathways. Cell clearance does not isolate the secretome from structural and immune functions.

Rank 3: Immune-clearance failure (Ε). Impaired surveillance and efferocytosis promote persistent cell states. HLA-E/PD-L1 and aged TRM EP2 perturbations provide defined mechanistic support. Immune metabolism and tissue injury also change; primary human immune-aging causation is not isolated.

Rank 4: Chronic repair or hyperfunction (Γ). Persistent repair programs can become harmful after useful transient responses. Reparative lung niches and transient-versus-prolonged SASP exposure fit this model. The origin of every senescent state is not a repair program.

Rank 5: Systemic senescence primacy (Γ). Senescent cells are the autonomous primary driver of organismal aging. Adult mouse clearance improves selected functions and survival. Incomplete clearance, unchanged phenotypes, beneficial populations and human efficacy gaps block systemic primacy.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Accumulated senescent cells causally drive age-related organismal dysfunction, and selective removal of these cells extends mammalian lifespan or human healthspan.

Restate the topic as the causal-driver claim. Apply the index weakest-link rule to accumulation, causal dysfunction and intervention benefit; report causal-contribution and clinical sensitivities separately. A contribution is not universal primacy, and senescence markers are not unique cell identities.

Selection: public-interest rank 12 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

Timed INK-ATTAC experiments moved beyond the earlier BubR1 progeroid result to natural adult aging. Original body text verifies two backgrounds, partial tissue clearance and a transgene-negative drug control; it also records variable maximum-life effects and unchanged motor, memory and exercise measures. This is strong evidence for selected contribution, with explicit organismal limits [2,4].

Transfer studies establish sufficiency of an added senescent burden for particular dysfunctions. Xu’s original text includes sham/non-senescent, autologous and immune-deficient controls, while late treatment improves median remaining survival. The latter is a post-treatment denominator, not whole-life extension. Late p21 clearance adds a distinct marker-defined platform [3,15,50].

Cell identity and timing are decisive. Original Hall passages demonstrate reversible macrophage markers; structural endothelial and lung sentinel cells may be useful. p21 wound/fracture and p16 aging populations differ. The 2026 p16-3MR validation challenge limits reliance on that construct while leaving the separate INK-ATTAC design to its own controls [7,16–18,32,48–56,61,62].

The human data are early translation. Open-label function or tissue-marker changes are not controlled healthspan proof. Original randomized IPF Methods/Results confirm six per arm, feasibility-oriented size, complete follow-up and no meaningful exploratory function signal. The bone RCT missed its primary endpoint; its later biomarker report reuses response-informed cohort strata. No durable general human healthy-life extension is shown [19–25].

PCC1 lifespan and PDGF-AA repair originals remain examined but are not used to carry threshold support because linked expressions of concern exist. Beneficial-context conclusions instead also rely on unflagged endothelial, lung-niche and transient-SASP experiments. Multiple tissue studies support contribution without establishing an autonomous single driver of systemic aging [9,32,49,56,58].

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: weakest-link. Preregistered weakest-link aggregation yields Β (SC1 Β, SC2 Ε, SC3 Ε). The causal-contribution sensitivity is Ε, not mere association. The application score acknowledges mouse survival and functional trajectories; human healthspan alone remains Γ. The bundled letter must not erase the causal contribution evidence or turn a real cellular state into a refuted phenomenon. Sensitivities: weakest-link Β; primary-subclaim Ε; scope-matched Ε.

Decisive-perturbation inventory and causal tally

[1] uPAR CAR-T cleared targeted cells and improved induced fibrosis or treated lung-cancer outcomes. These are disease models, not normal-aging survival; a linked author correction remains to be resolved.

[2] Adult INK-ATTAC clearance extended median life in both sexes and two mouse backgrounds with selected organ benefits. Body text shows partial tissue clearance, variable maximal survival and several unchanged functional endpoints; other p16-positive cells may be affected.

[3] Senescent-cell transfer impaired function; clearance rescued and late-life DQ increased median remaining survival. Artificial transferred burden is not normal initiation; 36% refers to post-treatment survival, not whole lifespan, and drug pleiotropy remains.

[4] INK-ATTAC clearance delayed selected pathologies in BubR1 progeroid mice, including late intervention. A progeroid chromosome-checkpoint disorder does not represent the full spectrum of normal aging.

[5] Late-life fisetin reduced markers and improved mouse health and survival. Cell selectivity and drug pleiotropy limit causal attribution; human explants do not demonstrate clinical benefit.

[6] Itpr2 loss reduced senescence and improved mouse survival and metabolic phenotypes. Calcium signalling and development are altered alongside senescence; clearance-mediated necessity is not isolated.

[7] Several clearance strategies worsened pulmonary vascular remodeling and endothelial loss in defined models. Harm maps cell type and disease context, not absence of all beneficial senolytic effects.

[8] Old-donor heart transplantation induced recipient dysfunction; donor senolysis reduced mtDNA release and improved physical outcomes. Surgery and old-organ transfer are induced stressors; multiple donor changes complicate cell-specific mediation.

[10] GPNMB ablation/vaccination improved selected mouse phenotypes and male progeroid survival. Antigen specificity and premature-aging survival do not establish general human antiaging efficacy.

[11] DQ reduced aged adipose inflammation and improved metabolic outcomes, with weaker liver/muscle marker effects. Drug-mediated metabolism and cell elimination are incompletely separated; tissue responses are heterogeneous.

[13] DQ delayed hearing decline in early-stage aging mice and modulated inflammatory signalling. NF-kappa-B binding provides a plausible non-senolytic action; strain-specific hearing loss restricts inference.

[14] Multiomic p21/TREM2 macrophage profiling and senolysis linked a defined macrophage state to aged-liver dysfunction. Human cirrhotic tissue is observational; macrophage activation and irreversible senescence need state-specific validation.

[15] Monthly p21-high cell clearance beginning at 20 months improved mouse function and median/maximal survival. Marker-defined populations are heterogeneous; one mouse platform is not universal mammalian or human primacy.

[16] DQ enhanced old-muscle regeneration but blunted young-muscle regeneration after injury. Age and repair timing determine effects; direct progenitor proliferation effects complicate senolysis mediation.

[17] DQ improved aged tibial endocortical loading response but not aged ulnar periosteal response. Bone surface, site and loading model define benefit; broad skeletal rejuvenation is unsupported.

[18] Senolytics improved remyelination in young/middle-aged but not aged mice; CCL11 impaired maturation. Old-age nonresponse and injury context constrain translation; preprint and published update are not independent reports.

[22] The 60-person bone RCT missed its primary CTx endpoint and had transient secondary formation-marker changes. High-p16 tertile benefits were exploratory; sustained clinical function and fracture reduction were not established.

[23] The 12-person randomized IPF pilot completed dosing but showed no meaningful between-group functional signal. Original Methods make feasibility/safety primary and report no multiplicity allowance; low power prevents definitive inefficacy inference.

[24] BCL-xL inhibition improved mouse diabetic retinal leakage; human phase 1 met safety objectives. Safety and preclinical function do not establish randomized human efficacy or general healthspan.

[26] Clearing p16-positive cells did not rescue young-mouse ovariectomy bone loss; short human estrogen treatment did not change senescence markers. Estrogen-deficiency bone loss is distinct from age-related bone loss and is a boundary rather than universal clearance failure.

[28] TRM EP2 reduction improved efferocytosis and multiple aged-mouse functional outcomes. Macrophage metabolism and immune clearance are intertwined; human tissue associations do not prove human aging mediation.

[29] Enhanced normally regulated Arf/p53 protected mice from damage and selected aging phenotypes. Tumour-suppressor signalling has broad functions; suppressing every senescence program cannot be assumed beneficial.

[30] Genetic and drug clearance improved function after bleomycin lung injury even when visible fibrosis remained. Early injury-model intervention is not reversal of established human IPF or normal-aging initiation.

[31] Multimodal profiling localized aged-muscle states and a senotherapeutic improved mouse strength. Human tissue evidence remains observational; myofiber senescent-like states differ from proliferative-cell arrest.

[32] Knock-in p16-high clearance removed indispensable endothelial populations and worsened barriers, fibrosis and health. Different reporter thresholds and cell coverage distinguish this system from INK-ATTAC; it does not negate all selected-cell clearance benefits.

[33] p16-mediated PD-L1 stabilization promoted persistence and Fc-engaging antibodies cleared defined populations. Checkpoint-mediated clearance is a particular immune mechanism; global human aging causation remains untested.

[34] Canagliflozin promoted clearance-related immune changes and extended progeroid mouse life. Glucose, metabolism and immunosurveillance all change; normal human lifespan benefit cannot be assigned to senolysis.

[35] Clearance reduced hepatic fat and inducing hepatocyte senescence increased lipid accumulation. Hepatic steatosis causality is narrower than organismal aging primacy; metabolic mediators remain multicomponent.

[36] Aged melanocyte secretome caused paracrine telomere dysfunction and epidermal-model atrophy reversible by intervention. Human skin sampling plus engineered culture is not an in vivo clinical aging-trajectory experiment.

[37] ABT263 cleared targeted populations and improved aged or irradiated stem-cell function. BCL-family inhibitors affect other cells; radiation injury and natural aging are separate tested contexts.

[38] Genetic and drug clearance improved metabolic, renal and cardiac outcomes in obese mice. Obesity-related dysfunction and normal-aging necessity are distinct scopes.

[39] INK-ATTAC glial clearance prevented tau pathology, neuronal loss and cognitive decline in PS19 mice. Preventive intervention in mutant-tau disease does not establish normal aging initiation or human senolytic efficacy.

[40] FOXO4-p53 interfering peptide restored selected functions in naturally aged and stressed/progeroid mice. Peptide specificity and disease rescue require independent replication before broad survival claims.

[41] Clearance restored neurogenesis and reduced anxiety-related behavior in obese mice. Obesity-specific behavioral mechanisms and a linked erratum constrain broad interpretation.

[43] Genetic and DQ treatment reduced aged-microglial p16 state and improved mouse cognition. Systemic and microglial effects are intertwined; aged-mouse cognition is not established human healthspan.

[44] Post-traumatic joint clearance reduced pain/pathology and improved cartilage-related outcomes. p16-3MR validation concerns require model-specific caution; orthogonal drug effects retain pleiotropy.

[45] HLA-E/NKG2A blockade enhanced immune recognition of cultured senescent cells; aged skin had higher HLA-E. Culture immune killing and tissue association do not prove human systemic aging mediation.

[46] Clearance reduced atherosclerotic lesion development and instability-related phenotypes in Ldlr-null mice. A lipid-driven disease model does not establish autonomous initiation of normal aging.

[47] Telomere damage marked post-mitotic cardiomyocyte states and clearance reduced mouse hypertrophy/fibrosis. Reduced specific pathology does not demonstrate global rejuvenation; post-mitotic senescence identity needs multiple features.

[48] Spatial profiling and p21-high clearance linked a wound-induced inflammatory population to slower closure. This injury population differs from p16-high reparative cells and does not define all age-related senescence.

[49] p16-positive niche fibroblasts promoted epithelial lung regeneration and p16 was functionally required. Postnatal sentinel cells are a useful boundary, not necessarily the same state as chronic harmful senescent cells.

[50] Inducible p21-Cre captured aged marker-high populations and clearance improved old-mouse function. Marker-defined targeting does not encompass all senescence; platform follow-ups are not independent system validation.

[51] p16-3MR clearance reduced osteoclast-progenitor markers but did not prevent age-related bone loss. Osteocytes were not eliminated; the null cannot falsify unengaged osteocyte-mediated pathology and reporter validation is disputed.

[52] Fisetin improved old-mouse vascular function, with nonadditive ex vivo genetic clearance supporting a senolytic route. Ex vivo nonadditivity is supportive rather than complete mediation; p16-3MR validation and drug pleiotropy limit certainty.

[53] A beta-gal-activated prodrug reduced markers/inflammation and restored aged-mouse function. Lysosomal activity is not senescence-exclusive and one pharmacologic platform does not establish broad specificity.

[54] p21-high clearance accelerated fracture repair but not aging bone loss; p16 clearance showed the converse boundary. Distinct injury and aging states defeat a universal single-marker interpretation; published and preprint records are one study.

[55] Aged skeletal stem-cell niche resisted youthful circulation; local BMP2/CSF1-antagonist combination restored regeneration. A multifactorial niche intervention does not isolate senescent-cell burden as sole causal driver.

[57] Topical ABT263 primed old skin and accelerated later wound closure with transient inflammation. Pretreatment and an induced local inflammatory response complicate attribution to cell removal alone.

[58] Transient SASP exposure promoted regenerative plasticity whereas prolonged exposure induced arrest. Exposure duration and injured tissues define scope; this is not a clinical senescent-cell delivery strategy.

[60] Survival-network targeting identified cell-type-dependent DQ senolysis and improved selected mouse functions. Different compounds target different cells; progeroid and radiation results must be separated from natural-aging benefit.

[61] Original Results show macrophage p16/beta-gal states respond reversibly to immune stimuli. Single markers cannot uniquely identify irreversible senescence; this does not invalidate multi-marker ATTAC evidence wholesale.

[62] A 2026 p16-3MR reevaluation failed to reproduce reporter and ablation performance with wild-type controls. This targets a particular construct; INK-ATTAC is distinct, and an accompanying response exists but its substantive contents were unavailable.

Tally: 52 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

Cap audit, precedence and Β/Γ/Δ boundary

Β binds the existence/age relationship. Ε is assigned to causal contribution and application within experimentally mapped mouse contexts; the universal single-species cap still blocks broader organismal primacy and human inference. SC3 is explicitly disjunctive, so a demonstrated mouse survival effect cannot be downgraded solely because human efficacy remains unproved. Neither the reporter challenge nor the two concern notices negates all orthogonal evidence; flagged reports receive no positive causal-threshold credit.

Gamma hard-rule audit: Biomarkers alone do not cross the aging-trajectory boundary. Species, strain, developmental timing and nonspecific interventions constrain the scope of each result.

SC1 cap: “Association with aging or age-related biomarkers without intervention-driven trajectory change caps at Β.” Multimarker and cell-resolved studies support accumulation in defined aged tissues. This age relationship remains observational and p16 alone is not exclusive.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Multimarker and cell-resolved studies support accumulation in defined aged tissues. This age relationship remains observational and p16 alone is not exclusive.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Selective adult clearance, transfer/clearance and orthogonal genetic/drug contrasts support causal contribution to defined mouse functions. Incomplete specificity, tissue-dependent harm and reporter concerns prevent universal necessity or systemic primacy.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. The disjunction is met in constrained mouse lifespan/healthspan settings, including adult p16 and late-life p21 clearance. Human durable functional benefit is a separate Γ sensitivity, not a condition silently added to the registered mammalian-or-human claim.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Independent longitudinal cell-resolved multimarker validation improves the age relationship; a causal claim requires a separately stated perturbation subclaim.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC2 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Independent marker-agnostic lineage targeting, restorative rescue and replicated natural-aging functional effects narrowing cell and secretome mediation would support Ζ.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC3 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC3 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Replicated survival plus meaningful functional trajectories across independent populations/modalities, with toxicity and intervention specificity resolved, would support Ζ; human efficacy requires a separate sufficiently powered clinical trial.

Upper ladder: Η and above remain reachable through convergent mechanisms and robust cross-context outcomes. Multiple mouse genetic/drug methods were considered. Shared marker identity, construct/platform reuse and drug pleiotropy limit convergence; human genetics, longitudinal tissue cohorts and clinical trials do not establish systemic aging primacy. Two concern-linked papers are excluded from threshold support.

Independence: These lines address different errors but cannot be counted as universal independent proof. INK-ATTAC follow-ups share a construct; p21 reports share a platform. IPF open-label and randomized subjects are distinct within one trial program; bone biomarker reanalysis reuses the original participants.

Timed genetic clearance [2, 15]: Reduces drug-only explanations; different markers still require identity controls.

Transfer with control cells and clearance [3]: Tests sufficiency and rejection alternatives; artificial burden remains.

Independent pharmacologic targets [37, 40, 53]: Reduces dependence on one compound; shared incomplete specificity persists.

Human randomized translation [22, 23]: Reduces uncontrolled practice/regression effects; power and endpoints remain limited.

Falsification and pitfalls

Clearance can harm structural or reparative populations. p16-high hepatic endothelium, pulmonary vascular models and lung sentinel fibroblasts; these reject untimed universal clearance benefit. Additional downgrade: False.

Randomized functional or primary endpoint benefit absent. IPF feasibility RCT had no meaningful function signal; bone trial primary CTx was null. Low power and surrogate endpoints constrain interpretation. Additional downgrade: False.

Marker reduction mistaken for functional rejuvenation. Human DKD and SenMayo panels are separated from durable clinical benefit.

Lifespan denominator inflation. Xu’s 36% is median remaining survival after old-age treatment, not a 36% increase in full lifespan.

Reporter systems treated as interchangeable. INK-ATTAC, p16-3MR, knock-in p16-high and p21-Cre are distinguished.

Concern notices ignored. PCC1 and PDGF-AA papers are flagged and do not support positive threshold crossings.

Subgroup or shared-cohort evidence counted as replication. Bone-trial exploratory tertiles and biomarker reanalysis retain their provenance.

Adversarial steelman: above, then below

For SC2/SC3, Ζ is plausible given genetic and pharmacologic convergence. It is withheld because cell identity, construct scope and nonspecific drug effects remain unresolved, and most independent outcomes remain mouse or disease-specific. The bundled score cannot rise above Β by replacing its observational SC1 with another causal claim.

Γ for the defined mouse contribution would ignore adult clearance in two backgrounds, controlled transfer and orthogonal late-life p21 results. Α for the bundle would disregard reproducible multimarker age relationships.

Retain Β for the registered bundle, Ε for scoped mouse causality/application and Γ for human healthspan alone. These sensitivities are declared rather than allowed to silently replace the gate.

Final score, causal direction and M/S/D

Preregistered weakest-link aggregation yields Β (SC1 Β, SC2 Ε, SC3 Ε). The causal-contribution sensitivity is Ε, not mere association. The application score acknowledges mouse survival and functional trajectories; human healthspan alone remains Γ. The bundled letter must not erase the causal contribution evidence or turn a real cellular state into a refuted phenomenon.

Senescent states arise after damage or repair, but transfer and clearance demonstrate feedback causal effects, so a purely downstream classification does not cover the scoped mechanism (steps 1–2). Clearance does not prevent all aging, rate limitation is unproved, and universal necessity is not shown (steps 3–4). Persistent defined populations amplify or maintain dysfunction, satisfying step 5, reinforcing / stabilizing factor.

Momentum: Decisive work underway. Late-life p21 clearance 2024, the bone RCT 2024, human biomarker reanalysis 2025, TRM clearance 2026 and reporter validation 2026 are named boundary tests in this corpus.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Register independent-site adult clearance of a multimarker-defined cell lineage with orthogonal non-marker-dependent targeting, then restore the targeted cells or a specified SASP mediator; pair this with a powered randomized clinical trial using a prospectively defined tissue-burden stratum.

Readout: Longitudinal organ function, frailty and survival in naturally aged animals; prespecified durable patient function or disease endpoint rather than marker reduction alone. Controls: Wild-type drug controls, sham transfer, cell identity/lineage validation, marker-negative clearance controls, sex/background replication, toxicity, mediator rescue and multiplicity-adjusted clinical endpoints. Supporting: Selective removal plus rescue identifies the dysfunctional lineage/mediator and durable effects replicate independently. Falsifying: Function changes without selective engagement, harm from structural loss, or a target-engaged powered human null.

RESEARCH TIMELINE

KNOWLEDGE GAPS

Which distinct p16, p21 and marker-negative states mediate which dysfunctions, and how can irreversible senescence be distinguished from reversible immune activation?

How general are the p16-3MR validation failure and the response, across colonies and original experimental contexts?

Which harmful persistent populations can be removed while preserving endothelial structure, transient repair and tumour suppression?

Can prospectively specified burden strata predict human benefit in an independent cohort after the current response-informed analyses?

Do senolytic clinical effects depend on actual cell killing rather than kinase, metabolic or anti-inflammatory actions?

How reproducible are lifespan and complete functional trajectories across independent sites and targets after concern-linked data are excluded?

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

62 primary reports were examined; five had selected original-body passages examined. Two original reports carry expressions of concern and receive no positive threshold credit. PCC1 notice content was examined: control-image similarity and unavailable raw data. The PDGF-AA concern linkage was verified but detailed notice content was unavailable. A mismatched public-body retrieval was rejected before source attribution. The Hori p16-3MR primary abstract was verified; its accompanying response lacked extractable substantive text here. Clinical enrollment, endpoint hierarchy and body access are recorded without claiming a complete paper/supplement audit.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-06.

Scope of checks. All 62 reference PMIDs verified against PubMed metadata (title, first author, year, journal, DOI) — 62/62 resolve to the stated record. Notice status was re-checked: the two expression-of-concern flags carried in the review (refs 9 and 56) are confirmed in the PubMed records, and no other reference carries a retraction or expression of concern. Ten load-bearing claims were spot-checked against the cited abstracts or retained original passages (INK-ATTAC adult clearance in two backgrounds and both sexes; the senescent-cell transfer experiment and the 36% figure; uPAR CAR-T disease-model scope; fisetin late-life treatment; monthly p21-high clearance from 20 months extending median and maximum lifespan; the twelve-participant randomised IPF pilot and its feasibility primary objective; the postmenopausal bone trial and its p16-variant biomarker follow-up). Scoring logic was re-derived from references/hsef-framework.md and SKILL.md Steps 3, 8–12: the index-prescribed weakest-link rule is applied as written (Β from SC1 Β, SC2 Ε, SC3 Ε), the reported alternatives (primary-subclaim Ε, scope-matched Ε) are arithmetically correct for this matrix, and the entry is correctly restated from a question into a gradeable causal claim before scoring.

Findings. No corrections were required. No factual, citation, scoring or internal-consistency error was demonstrable in this review.

Rejected findings (checked, no change). (a) Seven references carry a print/issue year one later than PubMed's e-publication year (refs 7, 8, 12, 16, 37, 48, 52); the print-year convention is used consistently and is not an error. (b) The possibility that SC2 or SC3 should carry Ζ rather than Ε was tested: replication exists across clearance platforms, but the review's own record of incomplete marker specificity, tissue-dependent harm and reporter-construct concerns leaves major alternative models narrowed rather than excluded, so Ε stands. (c) The bundled Β was tested against a primary-subclaim reading that would return Ε; the index prescribes weakest-link, the deviation rule was not invoked, and the alternative is reported as required. (d) Preprint-and-published pairs (refs 18 and 54) are correctly treated as one study rather than independent replication.

Residual limitations. Verification depth is abstract/metadata plus the five retained partial bodies; no complete-paper or supplement audit was performed by either model. The two expression-of-concern items remain unresolved upstream and are excluded from threshold support, as the review states.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06.

REFERENCES

1. Amor C, Feucht J, Leibold J et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020. PMID 32555459. DOI: 10.1038/s41586-020-2403-9. Access: abstract_metadata. Study: PMID32555459.

2. Baker DJ, Childs BG, Durik M et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016. PMID 26840489. DOI: 10.1038/nature16932. Access: full_text_partial. Study: INK-ATTAC lineage, two natural-aging cohorts.

3. Xu M, Pirtskhalava T, Farr JN et al. Senolytics improve physical function and increase lifespan in old age. Nature medicine. 2018. PMID 29988130. DOI: 10.1038/s41591-018-0092-9. Access: full_text_partial. Study: Xu transfer and aged-DQ experiments.

4. Baker DJ, Wijshake T, Tchkonia T et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011. PMID 22048312. DOI: 10.1038/nature10600. Access: abstract_metadata. Study: INK-ATTAC lineage, BubR1 cohort.

5. Yousefzadeh MJ, Zhu Y, McGowan SJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PMID 30279143. DOI: 10.1016/j.ebiom.2018.09.015. Access: abstract_metadata. Study: PMID30279143.

6. Ziegler DV, Vindrieux D, Goehrig D et al. Calcium channel ITPR2 and mitochondria-ER contacts promote cellular senescence and aging. Nature communications. 2021. PMID 33526781. DOI: 10.1038/s41467-021-20993-z. Access: abstract_metadata. Study: PMID33526781.

7. Born E, Lipskaia L, Breau M et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023. PMID 36515093. DOI: 10.1161/CIRCULATIONAHA.122.058794. Access: abstract_metadata. Study: PMID36515093.

8. Iske J, Roesel MJ, Martin F et al. Transplanting old organs promotes senescence in young recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2024. PMID 37913871. DOI: 10.1016/j.ajt.2023.10.013. Access: abstract_metadata. Study: PMID37913871.

9. Xu Q, Fu Q, Li Z et al. The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nature metabolism. 2021. PMID 34873338. DOI: 10.1038/s42255-021-00491-8. Access: abstract_metadata. Study: PMID34873338.

10. Suda M, Shimizu I, Katsuumi G et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature aging. 2021. PMID 37117524. DOI: 10.1038/s43587-021-00151-2. Access: abstract_metadata. Study: PMID37117524.

11. Islam MT, Tuday E, Allen S et al. Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging cell. 2023. PMID 36637079. DOI: 10.1111/acel.13767. Access: abstract_metadata. Study: PMID36637079.

12. Carver CM, Rodriguez SL, Atkinson EJ et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature aging. 2025. PMID 39658621. DOI: 10.1038/s43587-024-00752-7. Access: abstract_metadata. Study: PMID39658621.

13. Chen Y, Huang H, Luo Y et al. Senolytic treatment alleviates cochlear senescence and delays age-related hearing loss in C57BL/6J mice. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2025. PMID 40253743. DOI: 10.1016/j.phymed.2025.156772. Access: abstract_metadata. Study: PMID40253743.

14. Salladay-Perez IA, Avila I, Estrada L et al. p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease. Nature aging. 2026. PMID 41991686. DOI: 10.1038/s43587-026-01101-6. Access: abstract_metadata. Study: PMID41991686.

15. Wang B, Wang L, Gasek NS et al. Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function. Cell metabolism. 2024. PMID 39111286. DOI: 10.1016/j.cmet.2024.07.006. Access: abstract_metadata. Study: p21-Cre platform, late-life survival cohort.

16. Dungan CM, Murach KA, Zdunek CJ et al. Deletion of SA β-Gal+ cells using senolytics improves muscle regeneration in old mice. Aging cell. 2022. PMID 34904366. DOI: 10.1111/acel.13528. Access: abstract_metadata. Study: PMID34904366.

17. Cunningham CJ, Kok HJ, Farr JN et al. Senolytic Treatment Improves Responsiveness to Mechanical Loading in the Skeleton of Aged Mice. International journal of molecular sciences. 2025. PMID 41303716. DOI: 10.3390/ijms262211233. Access: abstract_metadata. Study: PMID41303716.

18. Gross PS, Durán-Laforet V, Ho LT et al. Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. Nature communications. 2025. PMID 40055369. DOI: 10.1038/s41467-025-57632-w. Access: abstract_metadata. Study: PMID40055369.

19. Hickson LJ, Langhi Prata LGP, Bobart SA et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. PMID 31542391. DOI: 10.1016/j.ebiom.2019.08.069. Access: abstract_metadata. Study: PMID31542391.

20. Gonzales MM, Garbarino VR, Kautz TF et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nature medicine. 2023. PMID 37679434. DOI: 10.1038/s41591-023-02543-w. Access: abstract_metadata. Study: PMID37679434.

21. Justice JN, Nambiar AM, Tchkonia T et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. PMID 30616998. DOI: 10.1016/j.ebiom.2018.12.052. Access: abstract_metadata. Study: IPF NCT02874989 open-label cohort.

22. Farr JN, Atkinson EJ, Achenbach SJ et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature medicine. 2024. PMID 38956196. DOI: 10.1038/s41591-024-03096-2. Access: abstract_metadata. Study: Bone NCT04313634.

23. Nambiar A, Kellogg D, Justice J et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine. 2023. PMID 36857968. DOI: 10.1016/j.ebiom.2023.104481. Access: full_text_partial. Study: IPF NCT02874989 separate randomized cohort.

24. Crespo-Garcia S, Fournier F, Diaz-Marin R et al. Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results. Nature medicine. 2024. PMID 38321220. DOI: 10.1038/s41591-024-02802-4. Access: abstract_metadata. Study: PMID38321220.

25. Farr JN, Monroe DG, Atkinson EJ et al. Characterization of Human Senescent Cell Biomarkers for Clinical Trials. Aging cell. 2025. PMID 39823170. DOI: 10.1111/acel.14489. Access: full_text_partial. Study: Bone NCT04313634.

26. Farr JN, Rowsey JL, Eckhardt BA et al. Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2019. PMID 30913313. DOI: 10.1002/jbmr.3729. Access: abstract_metadata. Study: PMID30913313.

27. Saul D, Kosinsky RL, Atkinson EJ et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nature communications. 2022. PMID 35974106. DOI: 10.1038/s41467-022-32552-1. Access: abstract_metadata. Study: SenMayo reused input cohorts; not independent efficacy.

28. Tan YJ, Conley TE, Yao F et al. Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging. Science (New York, N.Y.). 2026. PMID 42462036. DOI: 10.1126/science.aea3075. Access: abstract_metadata. Study: PMID42462036.

29. Matheu A, Maraver A, Klatt P et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007. PMID 17637672. DOI: 10.1038/nature05949. Access: abstract_metadata. Study: PMID17637672.

30. Schafer MJ, White TA, Iijima K et al. Cellular senescence mediates fibrotic pulmonary disease. Nature communications. 2017. PMID 28230051. DOI: 10.1038/ncomms14532. Access: abstract_metadata. Study: PMID28230051.

31. Zhang X, Habiballa L, Aversa Z et al. Characterization of cellular senescence in aging skeletal muscle. Nature aging. 2022. PMID 36147777. DOI: 10.1038/s43587-022-00250-8. Access: abstract_metadata. Study: PMID36147777.

32. Grosse L, Wagner N, Emelyanov A et al. Defined p16High Senescent Cell Types Are Indispensable for Mouse Healthspan. Cell metabolism. 2020. PMID 32485135. DOI: 10.1016/j.cmet.2020.05.002. Access: abstract_metadata. Study: PMID32485135.

33. Majewska J, Agrawal A, Mayo A et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nature cell biology. 2024. PMID 39103548. DOI: 10.1038/s41556-024-01465-0. Access: abstract_metadata. Study: PMID39103548.

34. Katsuumi G, Shimizu I, Suda M et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nature aging. 2024. PMID 38816549. DOI: 10.1038/s43587-024-00642-y. Access: abstract_metadata. Study: PMID38816549.

35. Ogrodnik M, Miwa S, Tchkonia T et al. Cellular senescence drives age-dependent hepatic steatosis. Nature communications. 2017. PMID 28608850. DOI: 10.1038/ncomms15691. Access: abstract_metadata. Study: PMID28608850.

36. Victorelli S, Lagnado A, Halim J et al. Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. The EMBO journal. 2019. PMID 31633821. DOI: 10.15252/embj.2019101982. Access: abstract_metadata. Study: PMID31633821.

37. Chang J, Wang Y, Shao L et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature medicine. 2016. PMID 26657143. DOI: 10.1038/nm.4010. Access: abstract_metadata. Study: PMID26657143.

38. Palmer AK, Xu M, Zhu Y et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging cell. 2019. PMID 30907060. DOI: 10.1111/acel.12950. Access: abstract_metadata. Study: PMID30907060.

39. Bussian TJ, Aziz A, Meyer CF et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature. 2018. PMID 30232451. DOI: 10.1038/s41586-018-0543-y. Access: abstract_metadata. Study: PMID30232451.

40. Baar MP, Brandt RMC, Putavet DA et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017. PMID 28340339. DOI: 10.1016/j.cell.2017.02.031. Access: abstract_metadata. Study: PMID28340339.

41. Ogrodnik M, Zhu Y, Langhi LGP et al. Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis. Cell metabolism. 2019. PMID 30612898. DOI: 10.1016/j.cmet.2018.12.008. Access: abstract_metadata. Study: PMID30612898.

42. Farr JN, Fraser DG, Wang H et al. Identification of Senescent Cells in the Bone Microenvironment. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2016. PMID 27341653. DOI: 10.1002/jbmr.2892. Access: abstract_metadata. Study: PMID27341653.

43. Ogrodnik M, Evans SA, Fielder E et al. Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice. Aging cell. 2021. PMID 33470505. DOI: 10.1111/acel.13296. Access: abstract_metadata. Study: PMID33470505.

44. Jeon OH, Kim C, Laberge RM et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nature medicine. 2017. PMID 28436958. DOI: 10.1038/nm.4324. Access: abstract_metadata. Study: PMID28436958.

45. Pereira BI, Devine OP, Vukmanovic-Stejic M et al. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition. Nature communications. 2019. PMID 31160572. DOI: 10.1038/s41467-019-10335-5. Access: abstract_metadata. Study: PMID31160572.

46. Childs BG, Baker DJ, Wijshake T et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science (New York, N.Y.). 2016. PMID 27789842. DOI: 10.1126/science.aaf6659. Access: abstract_metadata. Study: PMID27789842.

47. Anderson R, Lagnado A, Maggiorani D et al. Length-independent telomere damage drives post-mitotic cardiomyocyte senescence. The EMBO journal. 2019. PMID 30737259. DOI: 10.15252/embj.2018100492. Access: abstract_metadata. Study: PMID30737259.

48. Gasek NS, Yan P, Zhu J et al. Clearance of p21 highly expressing senescent cells accelerates cutaneous wound healing. Nature aging. 2025. PMID 39537987. DOI: 10.1038/s43587-024-00755-4. Access: abstract_metadata. Study: p21-Cre platform, wound cohort.

49. Reyes NS, Krasilnikov M, Allen NC et al. Sentinel p16INK4a+ cells in the basement membrane form a reparative niche in the lung. Science (New York, N.Y.). 2022. PMID 36227993. DOI: 10.1126/science.abf3326. Access: abstract_metadata. Study: PMID36227993.

50. Wang B, Wang L, Gasek NS et al. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. Nature aging. 2021. PMID 35024619. DOI: 10.1038/s43587-021-00107-6. Access: abstract_metadata. Study: p21-Cre platform.

51. Kim HN, Chang J, Iyer S et al. Elimination of senescent osteoclast progenitors has no effect on the age-associated loss of bone mass in mice. Aging cell. 2019. PMID 30773784. DOI: 10.1111/acel.12923. Access: abstract_metadata. Study: PMID30773784.

52. Mahoney SA, Venkatasubramanian R, Darrah MA et al. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence. Aging cell. 2024. PMID 38062873. DOI: 10.1111/acel.14060. Access: abstract_metadata. Study: PMID38062873.

53. Cai Y, Zhou H, Zhu Y et al. Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. Cell research. 2020. PMID 32341413. DOI: 10.1038/s41422-020-0314-9. Access: abstract_metadata. Study: PMID32341413.

54. Saul D, Doolittle ML, Rowsey JL et al. Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair. The Journal of clinical investigation. 2024. PMID 38753433. DOI: 10.1172/JCI179834. Access: abstract_metadata. Study: p21 fracture platform; published update.

55. Ambrosi TH, Marecic O, McArdle A et al. Aged skeletal stem cells generate an inflammatory degenerative niche. Nature. 2021. PMID 34381212. DOI: 10.1038/s41586-021-03795-7. Access: abstract_metadata. Study: PMID34381212.

56. Demaria M, Ohtani N, Youssef SA et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Developmental cell. 2014. PMID 25499914. DOI: 10.1016/j.devcel.2014.11.012. Access: abstract_metadata. Study: PMID25499914.

57. Shvedova M, Thanapaul RJRS, Ha J et al. Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing. Aging. 2024. PMID 39630941. DOI: 10.18632/aging.206165. Access: abstract_metadata. Study: PMID39630941.

58. Ritschka B, Storer M, Mas A et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes & development. 2017. PMID 28143833. DOI: 10.1101/gad.290635.116. Access: abstract_metadata. Study: PMID28143833.

59. Krishnamurthy J, Torrice C, Ramsey MR et al. Ink4a/Arf expression is a biomarker of aging. The Journal of clinical investigation. 2004. PMID 15520862. DOI: 10.1172/JCI22475. Access: abstract_metadata. Study: PMID15520862.

60. Zhu Y, Tchkonia T, Pirtskhalava T et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging cell. 2015. PMID 25754370. DOI: 10.1111/acel.12344. Access: abstract_metadata. Study: PMID25754370.

61. Hall BM, Balan V, Gleiberman AS et al. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging. 2017. PMID 28768895. DOI: 10.18632/aging.101268. Access: full_text_partial. Study: PMID28768895.

62. Hori N, Kawamoto S, Uemura K et al. Limitations of the p16-3MR mouse model for detecting and eliminating senescent cells. EMBO reports. 2026. PMID 42209826. DOI: 10.1038/s44319-026-00802-8. Access: abstract_metadata. Study: PMID42209826.

Source-specific evidence cards

[1] Senolytic CAR T cells reverse senescence-associated pathologies.

Shows: uPAR CAR-T cleared targeted cells and improved induced fibrosis or treated lung-cancer outcomes.

Does not show: These are disease models, not normal-aging survival; a linked author correction remains to be resolved.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID38383793. Subclaims: SC2.

[2] Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan.

Shows: Adult INK-ATTAC clearance extended median life in both sexes and two mouse backgrounds with selected organ benefits.

Does not show: Body text shows partial tissue clearance, variable maximal survival and several unchanged functional endpoints; other p16-positive cells may be affected.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 6:Discussion:paragraph0, 7:METHODS:paragraph0, 7:METHODS:paragraph1, 1:ATTAC clears senescent adipocyte progenitor cells, 2:Clearance by ATTAC is partial and tissue selective, 3:p16Ink4a-positive cells shorten lifespan and healthspan. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[3] Senolytics improve physical function and increase lifespan in old age.

Shows: Senescent-cell transfer impaired function; clearance rescued and late-life DQ increased median remaining survival.

Does not show: Artificial transferred burden is not normal initiation; 36% refers to post-treatment survival, not whole lifespan, and drug pleiotropy remains.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph15, 3:Online Methods:paragraph14, 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph2, 1:Results:paragraph4, 1:Results:paragraph5, 1:Results:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[4] Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.

Shows: INK-ATTAC clearance delayed selected pathologies in BubR1 progeroid mice, including late intervention.

Does not show: A progeroid chromosome-checkpoint disorder does not represent the full spectrum of normal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[5] Fisetin is a senotherapeutic that extends health and lifespan.

Shows: Late-life fisetin reduced markers and improved mouse health and survival.

Does not show: Cell selectivity and drug pleiotropy limit causal attribution; human explants do not demonstrate clinical benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[6] Calcium channel ITPR2 and mitochondria-ER contacts promote cellular senescence and aging.

Shows: Itpr2 loss reduced senescence and improved mouse survival and metabolic phenotypes.

Does not show: Calcium signalling and development are altered alongside senescence; clearance-mediated necessity is not isolated.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[7] Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.

Shows: Several clearance strategies worsened pulmonary vascular remodeling and endothelial loss in defined models.

Does not show: Harm maps cell type and disease context, not absence of all beneficial senolytic effects.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[8] Transplanting old organs promotes senescence in young recipients.

Shows: Old-donor heart transplantation induced recipient dysfunction; donor senolysis reduced mtDNA release and improved physical outcomes.

Does not show: Surgery and old-organ transfer are induced stressors; multiple donor changes complicate cell-specific mediation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[9] The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice.

Shows: The PCC1 original report described improved old-mouse function and survival.

Does not show: A 2026 editorial expression of concern identifies a similar control image and unavailable underlying raw data; no positive causal-threshold credit is assigned.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ExpressionOfConcernIn: PMID41731120. Subclaims: SC2, SC3.

[10] Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice.

Shows: GPNMB ablation/vaccination improved selected mouse phenotypes and male progeroid survival.

Does not show: Antigen specificity and premature-aging survival do not establish general human antiaging efficacy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[11] Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age.

Shows: DQ reduced aged adipose inflammation and improved metabolic outcomes, with weaker liver/muscle marker effects.

Does not show: Drug-mediated metabolism and cell elimination are incompletely separated; tissue responses are heterogeneous.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[12] IL-23R is a senescence-linked circulating and tissue biomarker of aging.

Shows: IL-23R and other circulating/tissue signals tracked age and responded to several clearance approaches.

Does not show: A responsive biomarker does not uniquely count senescent cells or establish functional aging mediation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[13] Senolytic treatment alleviates cochlear senescence and delays age-related hearing loss in C57BL/6J mice.

Shows: DQ delayed hearing decline in early-stage aging mice and modulated inflammatory signalling.

Does not show: NF-kappa-B binding provides a plausible non-senolytic action; strain-specific hearing loss restricts inference.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[14] p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease.

Shows: Multiomic p21/TREM2 macrophage profiling and senolysis linked a defined macrophage state to aged-liver dysfunction.

Does not show: Human cirrhotic tissue is observational; macrophage activation and irreversible senescence need state-specific validation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[15] Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function.

Shows: Monthly p21-high cell clearance beginning at 20 months improved mouse function and median/maximal survival.

Does not show: Marker-defined populations are heterogeneous; one mouse platform is not universal mammalian or human primacy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[16] Deletion of SA β-Gal+ cells using senolytics improves muscle regeneration in old mice.

Shows: DQ enhanced old-muscle regeneration but blunted young-muscle regeneration after injury.

Does not show: Age and repair timing determine effects; direct progenitor proliferation effects complicate senolysis mediation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[17] Senolytic Treatment Improves Responsiveness to Mechanical Loading in the Skeleton of Aged Mice.

Shows: DQ improved aged tibial endocortical loading response but not aged ulnar periosteal response.

Does not show: Bone surface, site and loading model define benefit; broad skeletal rejuvenation is unsupported.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] Senescent-like microglia limit remyelination through the senescence associated secretory phenotype.

Shows: Senolytics improved remyelination in young/middle-aged but not aged mice; CCL11 impaired maturation.

Does not show: Old-age nonresponse and injury context constrain translation; preprint and published update are not independent reports.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID38826296. Subclaims: SC2.

[19] Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.

Shows: Nine kidney-disease participants had lower skin/adipose marker burden after short DQ treatment.

Does not show: Open-label biomarkers do not demonstrate renal functional benefit; linked corrigendum details remain unresolved.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID31982828. Subclaims: SC1, SC3.

[20] Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.

Shows: Five AD participants completed feasibility treatment; dasatinib entered CSF but cognition/imaging did not significantly change.

Does not show: Uncontrolled small safety study is not an efficacy trial; quercetin was undetectable in CSF.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID37162971. Subclaims: SC3.

[21] Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

Shows: Open-label IPF feasibility study reported improved walking/gait/chair measures but unchanged lung function.

Does not show: No placebo control and multiple secondary outcomes prevent attribution of human healthspan benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[22] Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.

Shows: The 60-person bone RCT missed its primary CTx endpoint and had transient secondary formation-marker changes.

Does not show: High-p16 tertile benefits were exploratory; sustained clinical function and fracture reduction were not established.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[23] Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.

Shows: The 12-person randomized IPF pilot completed dosing but showed no meaningful between-group functional signal.

Does not show: Original Methods make feasibility/safety primary and report no multiplicity allowance; low power prevents definitive inefficacy inference.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods, 2:Results. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[24] Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.

Shows: BCL-xL inhibition improved mouse diabetic retinal leakage; human phase 1 met safety objectives.

Does not show: Safety and preclinical function do not establish randomized human efficacy or general healthspan.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[25] Characterization of Human Senescent Cell Biomarkers for Clinical Trials.

Shows: T-cell p16 variants and a SASP panel refined an exploratory bone-trial responder association.

Does not show: Body text confirms reuse of the same trial and response-informed tertile analyses; this is not independent validation of efficacy.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Methods:paragraph8, 2:Results:paragraph2, 2:Results:paragraph5, 2:Results:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[26] Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans.

Shows: Clearing p16-positive cells did not rescue young-mouse ovariectomy bone loss; short human estrogen treatment did not change senescence markers.

Does not show: Estrogen-deficiency bone loss is distinct from age-related bone loss and is a boundary rather than universal clearance failure.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[27] A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues.

Shows: SenMayo enrichment and single-cell analysis identified senescence-related tissue states and clearance-responsive panels.

Does not show: Gene-set expression is not uniquely irreversible arrest or proof of mechanistic clinical benefit; some input cohorts are reused.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[28] Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.

Shows: TRM EP2 reduction improved efferocytosis and multiple aged-mouse functional outcomes.

Does not show: Macrophage metabolism and immune clearance are intertwined; human tissue associations do not prove human aging mediation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[29] Delayed ageing through damage protection by the Arf/p53 pathway.

Shows: Enhanced normally regulated Arf/p53 protected mice from damage and selected aging phenotypes.

Does not show: Tumour-suppressor signalling has broad functions; suppressing every senescence program cannot be assumed beneficial.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[30] Cellular senescence mediates fibrotic pulmonary disease.

Shows: Genetic and drug clearance improved function after bleomycin lung injury even when visible fibrosis remained.

Does not show: Early injury-model intervention is not reversal of established human IPF or normal-aging initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[31] Characterization of cellular senescence in aging skeletal muscle.

Shows: Multimodal profiling localized aged-muscle states and a senotherapeutic improved mouse strength.

Does not show: Human tissue evidence remains observational; myofiber senescent-like states differ from proliferative-cell arrest.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[32] Defined p16High Senescent Cell Types Are Indispensable for Mouse Healthspan.

Shows: Knock-in p16-high clearance removed indispensable endothelial populations and worsened barriers, fibrosis and health.

Does not show: Different reporter thresholds and cell coverage distinguish this system from INK-ATTAC; it does not negate all selected-cell clearance benefits.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[33] p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells.

Shows: p16-mediated PD-L1 stabilization promoted persistence and Fc-engaging antibodies cleared defined populations.

Does not show: Checkpoint-mediated clearance is a particular immune mechanism; global human aging causation remains untested.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[34] SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.

Shows: Canagliflozin promoted clearance-related immune changes and extended progeroid mouse life.

Does not show: Glucose, metabolism and immunosurveillance all change; normal human lifespan benefit cannot be assigned to senolysis.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[35] Cellular senescence drives age-dependent hepatic steatosis.

Shows: Clearance reduced hepatic fat and inducing hepatocyte senescence increased lipid accumulation.

Does not show: Hepatic steatosis causality is narrower than organismal aging primacy; metabolic mediators remain multicomponent.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[36] Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction.

Shows: Aged melanocyte secretome caused paracrine telomere dysfunction and epidermal-model atrophy reversible by intervention.

Does not show: Human skin sampling plus engineered culture is not an in vivo clinical aging-trajectory experiment.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[37] Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice.

Shows: ABT263 cleared targeted populations and improved aged or irradiated stem-cell function.

Does not show: BCL-family inhibitors affect other cells; radiation injury and natural aging are separate tested contexts.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[38] Targeting senescent cells alleviates obesity-induced metabolic dysfunction.

Shows: Genetic and drug clearance improved metabolic, renal and cardiac outcomes in obese mice.

Does not show: Obesity-related dysfunction and normal-aging necessity are distinct scopes.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[39] Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline.

Shows: INK-ATTAC glial clearance prevented tau pathology, neuronal loss and cognitive decline in PS19 mice.

Does not show: Preventive intervention in mutant-tau disease does not establish normal aging initiation or human senolytic efficacy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[40] Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.

Shows: FOXO4-p53 interfering peptide restored selected functions in naturally aged and stressed/progeroid mice.

Does not show: Peptide specificity and disease rescue require independent replication before broad survival claims.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[41] Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis.

Shows: Clearance restored neurogenesis and reduced anxiety-related behavior in obese mice.

Does not show: Obesity-specific behavioral mechanisms and a linked erratum constrain broad interpretation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID31067450. Subclaims: SC2.

[42] Identification of Senescent Cells in the Bone Microenvironment.

Shows: Aged bone lineages had elevated multiple markers, including osteocyte telomere damage and chromatin changes.

Does not show: Cross-sectional multi-marker identity improves existence evidence but does not by itself show causal bone loss.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[43] Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice.

Shows: Genetic and DQ treatment reduced aged-microglial p16 state and improved mouse cognition.

Does not show: Systemic and microglial effects are intertwined; aged-mouse cognition is not established human healthspan.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[44] Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment.

Shows: Post-traumatic joint clearance reduced pain/pathology and improved cartilage-related outcomes.

Does not show: p16-3MR validation concerns require model-specific caution; orthogonal drug effects retain pleiotropy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[45] Senescent cells evade immune clearance via HLA-E-mediated NK and CD8+ T cell inhibition.

Shows: HLA-E/NKG2A blockade enhanced immune recognition of cultured senescent cells; aged skin had higher HLA-E.

Does not show: Culture immune killing and tissue association do not prove human systemic aging mediation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[46] Senescent intimal foam cells are deleterious at all stages of atherosclerosis.

Shows: Clearance reduced atherosclerotic lesion development and instability-related phenotypes in Ldlr-null mice.

Does not show: A lipid-driven disease model does not establish autonomous initiation of normal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[47] Length-independent telomere damage drives post-mitotic cardiomyocyte senescence.

Shows: Telomere damage marked post-mitotic cardiomyocyte states and clearance reduced mouse hypertrophy/fibrosis.

Does not show: Reduced specific pathology does not demonstrate global rejuvenation; post-mitotic senescence identity needs multiple features.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[48] Clearance of p21 highly expressing senescent cells accelerates cutaneous wound healing.

Shows: Spatial profiling and p21-high clearance linked a wound-induced inflammatory population to slower closure.

Does not show: This injury population differs from p16-high reparative cells and does not define all age-related senescence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[49] Sentinel p16INK4a+ cells in the basement membrane form a reparative niche in the lung.

Shows: p16-positive niche fibroblasts promoted epithelial lung regeneration and p16 was functionally required.

Does not show: Postnatal sentinel cells are a useful boundary, not necessarily the same state as chronic harmful senescent cells.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[50] An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo.

Shows: Inducible p21-Cre captured aged marker-high populations and clearance improved old-mouse function.

Does not show: Marker-defined targeting does not encompass all senescence; platform follow-ups are not independent system validation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[51] Elimination of senescent osteoclast progenitors has no effect on the age-associated loss of bone mass in mice.

Shows: p16-3MR clearance reduced osteoclast-progenitor markers but did not prevent age-related bone loss.

Does not show: Osteocytes were not eliminated; the null cannot falsify unengaged osteocyte-mediated pathology and reporter validation is disputed.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[52] Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence.

Shows: Fisetin improved old-mouse vascular function, with nonadditive ex vivo genetic clearance supporting a senolytic route.

Does not show: Ex vivo nonadditivity is supportive rather than complete mediation; p16-3MR validation and drug pleiotropy limit certainty.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[53] Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice.

Shows: A beta-gal-activated prodrug reduced markers/inflammation and restored aged-mouse function.

Does not show: Lysosomal activity is not senescence-exclusive and one pharmacologic platform does not establish broad specificity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[54] Osteochondroprogenitor cells and neutrophils expressing p21 and senescence markers modulate fracture repair.

Shows: p21-high clearance accelerated fracture repair but not aging bone loss; p16 clearance showed the converse boundary.

Does not show: Distinct injury and aging states defeat a universal single-marker interpretation; published and preprint records are one study.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID38370844. Subclaims: SC2.

[55] Aged skeletal stem cells generate an inflammatory degenerative niche.

Shows: Aged skeletal stem-cell niche resisted youthful circulation; local BMP2/CSF1-antagonist combination restored regeneration.

Does not show: A multifactorial niche intervention does not isolate senescent-cell burden as sole causal driver.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[56] An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA.

Shows: The original PDGF-AA report proposed reparative senescence and rescue of wound closure.

Does not show: A linked 2026 expression of concern is present; detailed notice content was not obtained, so this paper receives no causal-threshold credit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ExpressionOfConcernIn: PMID42412492. Subclaims: SC2.

[57] Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing.

Shows: Topical ABT263 primed old skin and accelerated later wound closure with transient inflammation.

Does not show: Pretreatment and an induced local inflammatory response complicate attribution to cell removal alone.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID39229113. Subclaims: SC2.

[58] The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration.

Shows: Transient SASP exposure promoted regenerative plasticity whereas prolonged exposure induced arrest.

Does not show: Exposure duration and injured tissues define scope; this is not a clinical senescent-cell delivery strategy.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[59] Ink4a/Arf expression is a biomarker of aging.

Shows: Ink4a/Arf increased in defined aged tissue compartments and correlated with pathology/CR responses.

Does not show: Expression is a marker association, not an exclusive cell count or causal aging proof.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[60] The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.

Shows: Survival-network targeting identified cell-type-dependent DQ senolysis and improved selected mouse functions.

Does not show: Different compounds target different cells; progeroid and radiation results must be separated from natural-aging benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[61] p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli.

Shows: Original Results show macrophage p16/beta-gal states respond reversibly to immune stimuli.

Does not show: Single markers cannot uniquely identify irreversible senescence; this does not invalidate multi-marker ATTAC evidence wholesale.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:RESULTS:paragraph3, 1:RESULTS:paragraph4, 1:RESULTS:paragraph5, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[62] Limitations of the p16-3MR mouse model for detecting and eliminating senescent cells.

Shows: A 2026 p16-3MR reevaluation failed to reproduce reporter and ablation performance with wild-type controls.

Does not show: This targets a particular construct; INK-ATTAC is distinct, and an accompanying response exists but its substantive contents were unavailable.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• SHA256.txt
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• senescence-aging-driver.review.md
• senescence-aging-driver.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 62 · load-bearing claims: 66 · verified: 66 · unverified: 0 · contradicted: 0 · schema 5.3